Immunic Inc. (NASDAQ: IMUX) announced the appointment of Erik Lundgren as chief executive officer, effective May 22, 2026, with employment beginning June 1, 2026. Lundgren succeeds Daniel Vitt, who will remain on the company's board of directors and retain responsibility for scientific strategy.

Lundgren brings nearly two decades of biopharmaceutical experience, most recently serving as senior vice president of commercial portfolio organization at Genentech. He previously held the role of general manager at Roche Czech Republic and served as senior marketing director supporting the launch of Ocrevus, a multiple sclerosis treatment.

The appointment comes as Immunic advances its lead drug candidate vidofludimus calcium through late-stage clinical development, including a pivotal phase 3 program in relapsing multiple sclerosis with data expected by year-end 2026. The company is also preparing for a planned phase 3 program in primary progressive multiple sclerosis.

Immunic's compensation committee granted Lundgren an initial equity option to purchase 1,000,000 shares of common stock under the company's 2026 inducement equity compensation plan. The options will vest 25% on the one-year anniversary of May 22, 2026, with the remainder vesting monthly over 36 installments.

Lundgren earned a bachelor's degree in public policy from Duke University and a master's degree in business administration from Harvard Business School. During his tenure at Genentech, he also supported launches of oncology medicines including Kadcyla and Zelboraf.

Immunic is a late-stage biotechnology company developing oral therapies for neurologic diseases, with vidofludimus calcium as its primary development program targeting multiple sclerosis treatment.